Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HyQvia vs Kiovig in CIDP
2014-005496-87Phase 3Completed
- Sponsor
- Baxalta
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Human normal immunoglobulin G in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Baxalta. Primary endpoint: Primary endpoints (Epoch 1: SC Treatment Period). Started Sep 2015; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2014-005496-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005496-87.